Patents Assigned to Genentech
  • METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
    Publication number: 20100061996
    Abstract: The invention provides methods and compositions for modulating hepsin activity and the uPA/plasmin pathway, in particular by regulating pro-uPA activation by hepsin.
    Type: Application
    Filed: June 20, 2007
    Publication date: March 11, 2010
    Applicant: GENENTECH, INC.
    Inventors: Daniel K. Kirchhofer, Paul M. Moran
  • Treatment of cancer with a novel anti-IL13 monoclonal antibody
    Patent number: 7674459
    Abstract: The present invention relates to the treatment of IL13 dependent neoplastic disorders comprising the administration of novel anti-IL13 antibodies, The invention also includes diagnosing such tumors or cancer using the antibodies of the present invention to detect overexpression of IL13 in the patient.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: March 9, 2010
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Matthew Moyle
  • Methods for tissue analysis
    Patent number: 7674589
    Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
    Type: Grant
    Filed: December 9, 2008
    Date of Patent: March 9, 2010
    Assignee: Genentech, Inc.
    Inventors: Robert L. Cohen, Mary Beth Gardiner, Mark X. Sliwkowski, Gregory T. Stelzer
  • ARYLSULFONAMIDE COMPOUNDS
    Publication number: 20100056517
    Abstract: The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mimic the biological activity of BH3-only proteins and are capable of binding to and neutralizing pro-survival Bcl-2 proteins: wherein A1, A2, B1, B2, B3, X, Z, R1, R2, R3 and t are as described herein. The invention also relates to processes of preparing the benzenesulfonamide compounds that mimic portions of peptides and proteins, and to the use of such compounds in the regulation of cell death and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death.
    Type: Application
    Filed: November 15, 2007
    Publication date: March 4, 2010
    Applicants: GENENTECH, INC., WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARC
    Inventors: Jonathan Bayldon Baell, Guillaume Laurent Lessene, Brad Edmund Sleebs, Wayne J. Fairbrother, John A. Flygare, Michael F.T. Koeler
  • Mammalian cell culture process
    Patent number: 7666416
    Abstract: The present invention relates to novel process for the preparation of glycoproteins by mammalian-cell culture wherein the sialic acid content of the glycoprotein' produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for processes in which the sialic acid content of the glycoprotein is modified by changes in cell culture parameters which affect cell specific productivity. Preferred embodiments of the invention include cell culture processes in the osmolality of the cell culture is controlled as well as the concentration of a transcription enhancer during the production phase of the cell culture. The invention further provides for novel preparations of-soluble type 1 tumor necrosis factor immunoglobulin G1 and their uses in the treatment of inflammatory or immune related disorders.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: February 23, 2010
    Assignee: Genentech, Inc.
    Inventors: Tina Etcheverry, Thomas Ryll
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20100040634
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: October 21, 2009
    Publication date: February 18, 2010
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • ErbB4 receptor-specific neuregulin related ligands and uses therefor
    Patent number: 7662585
    Abstract: The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: February 16, 2010
    Assignee: Genentech, Inc.
    Inventors: Paul J. Godowski, Melanie Rose Mark, Dong-Xiao Zhang
  • Mass spectrometry of antibody conjugates
    Patent number: 7662936
    Abstract: Methods to detect, screen, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates of Formula I, antibodies, and fragments and metabolites thereof, by affinity separation, chromatography, and mass spectrometry are disclosed. Ab-(L-D)p??I wherein Ab is an antibody; D is a drug moiety; L is a linker covalently attached to Ab, and covalently attached to D; and p is 1, 2, 3, 4, 5, 6, 7, or 8.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: February 16, 2010
    Assignee: Genentech, Inc.
    Inventors: Miryam Kadkhodayan, Emily Mann
  • Process for reducing biomass-biomass or biomass—resin interactions
    Patent number: 7662934
    Abstract: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: February 16, 2010
    Assignee: Genentech, Inc.
    Inventor: Richard L. Gehant
  • Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
    Patent number: 7662926
    Abstract: The present application describes antibodies that selectively bind human Fc?RIIB, with little or no binding to other human Fc?Rs, e.g., human Fc?RIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds Fc?RIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: February 16, 2010
    Assignee: Genentech, Inc.
    Inventors: Andrew C. Chan, Robert L. Shields, Lawren Wu
  • ENRICHMENT METHOD FOR VARIANT PROTEINS WITH ALTERED BINDING PROPERTIES
    Publication number: 20100035236
    Abstract: A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.
    Type: Application
    Filed: July 24, 2009
    Publication date: February 11, 2010
    Applicant: Genentech, Inc.
    Inventors: Lisa J. GARRARD, Dennis J. Henner, Steven Bass, Ronald Greene, Henry B. Lowman, James A. Wells, David J. Matthews
  • ErbB2 and ErbB3 chimeric heteromultimer adhesins
    Patent number: 7659368
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: February 9, 2010
    Assignee: Genentech, Inc.
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • METHODS AND COMPOSITIONS FOR MODULATING HYPERSTABILIZED C-MET
    Publication number: 20100028337
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.
    Type: Application
    Filed: September 29, 2009
    Publication date: February 4, 2010
    Applicant: Genentech, Inc.
    Inventors: Monica Kong-Beltran, Dineli M. Wickramasinghe
  • Methods and compositions for increasing antibody production
    Patent number: 7655783
    Abstract: The invention provides methods and compositions for improved expression and production of recombinant antibodies in host cell expression systems. In particular, prokaryotic expression and production of antibodies with modified hinge cysteine residues are provided. The invention further provides compositions, kits and articles of manufacture for practicing methods of the present invention.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: February 2, 2010
    Assignee: Genentech, Inc.
    Inventors: Dorothea Reilly, Daniel Yansura
  • Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke
    Patent number: 7655230
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: February 2, 2010
    Assignee: Genentech, Inc.
    Inventors: Martin M. Bednar, Cordell E. Gross, Linda J. Gross, legal representative, G. Roger Thomas
  • Methods of Treating Autoimmune Diseases Using CD4 Antibodies
    Publication number: 20100021460
    Abstract: Methods of treating autoimmune disorders in mammalian subjects using non-depleting CD4 antibodies, alone or in combination with other compounds, are provided.
    Type: Application
    Filed: July 14, 2009
    Publication date: January 28, 2010
    Applicant: Genentech, Inc.
    Inventors: Rong Deng, Paul J. Fielder, Henry B. Lowman, Eric Stefanich, Yanan Zheng
  • METHODS AND COMPOSITIONS FOR TARGETING HEPSIN
    Publication number: 20100021474
    Abstract: Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: June 20, 2007
    Publication date: January 28, 2010
    Applicant: GENENTECH, INC.
    Inventors: Daniel K. Kirchhofer, Rajesh Vij
  • Injection vehicle for polymer-based formulations
    Patent number: 7651703
    Abstract: The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: January 26, 2010
    Assignee: Genentech, Inc.
    Inventors: Jeffrey L. Cleland, Xanthe M. Lam, Franklin Okumu
  • PRETREATMENT OF A BIOLOGICAL SAMPLE FROM AN AUTOIMMUNE DISEASE SUBJECT
    Publication number: 20100015055
    Abstract: The present application describes a method for pretreating a biological sample from an autoimmune disease subject in order to avoid interference, especially where the sample is to be subjected to a cell-based biological activity assay, such as a neutralizing antibody assay.
    Type: Application
    Filed: August 31, 2009
    Publication date: January 21, 2010
    Applicant: Genentech, Inc.
    Inventors: Krista McCutcheon, An Song
  • ANTIBODY FORMULATIONS
    Publication number: 20100015157
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: September 4, 2009
    Publication date: January 21, 2010
    Applicant: Genentech, Inc.
    Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen